Research progress in the inhibition of breast cancer metastasis by co-delivering paclitaxel nanodrugs / 国际生物医学工程杂志

ABSTRACT

Breast cancer is the malignancy with the highest number of new cases worldwide and is the leading cause of cancer-related deaths in women. More than 90% of breast cancer-related deaths are related to its metastasis. Paclitaxel, one of the most commonly used chemotherapeutic agents for the treatment of breast cancer, is an effective means of inhibiting breast cancer metastasis. To overcome the adverse effects of paclitaxel's hydrophobicity and its co-solvent, its nano-drugs have been a hot research topic. Some nanomedicines delivering paclitaxel have been used in clinical practice and have shown satisfactory efficacy and good tolerability. In this review, the research progress on the inhibition of breast cancer metastasis by co-delivered paclitaxel nanomedicines was summarized with the aim of providing a reference for their anti-breast cancer metastasis research.